MedTrace Logo

Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)

NCT01509625 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 272

Last updated 2016-06-01

Study results available
· View outcomes & findings →

Summary

This retrospective observational study is designed to assess the response to treatment with fulvestrant at a dose of 500 mg/month with a loading dose of 500 mg (LD-500), in terms of progression free survival (PFS), overall survival (OS), and clinical benefit rate (CBR), in post-menopausal women with Advanced Breast Cancer and estrogen receptor positive, who were treated with this medicinal product and at said dose after having progressed with a previous anti-estrogen therapy. During this study, a retrospective data collection will be carried out using the information contained in the Clinical History of said patients, provided that the treatment with fulvestrant at a dose of 500 mg and LD-500.

Conditions

  • Malignant Neoplasm of Breast Stage IV

Interventions

DRUG

Fulvestrant

It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.

Sponsors & Collaborators

  • Isabel Blancas

    lead OTHER

Principal Investigators

  • Isabel Blancas, MD

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-01-31
Completion
2014-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01509625 on ClinicalTrials.gov